Printer Friendly

MARION MERRELL DOW INC. AND MITSUBISHI KASEI CORP. ANNOUNCE NORTH AMERICAN COLLABORATION

 KANSAS CITY, Mo., April 8 /PRNewswire/ -- Marion Merrell Dow Inc. and Mitsubishi Kasei Corp. today announced a collaboration for the North American development and marketing of pharmaceutical products discovered by Mitsubishi Kasei. Financial terms of the agreement were not disclosed.
 Under the agreement, Marion Merrell Dow and Mitsubishi Kasei will review Mitsubishi Kasei compounds that are currently in clinical development in Japan, as well as compounds that enter clinical trials in the next seven years. Selected compounds will either be licensed for North America, with Marion Merrell Dow developing and marketing the new drugs and Mitsubishi Kasei supplying the bulk ingredients, or they will be jointly developed and marketed in North America.
 The companies have begun reviewing initial candidates for inclusion in the collaboration. Mitsubishi Kasei's pipeline includes new chemical entities in therapeutic fields in which Marion Merrell Dow has an established or emerging presence, such as cardiovascular, respiratory and gastrointestinal medicine, as well as diseases of the central nervous system and metabolic disorders.
 "This strategic alliance supplements Marion Merrell Dow's pipeline of potential new drugs from our own discovery research and offers the potential to make important new medications available to patients in the United States and Canada," said Fred W. Lyons Jr., president and chief executive officer of Marion Merrell Dow. "We are very pleased to enter this collaboration with Mitsubishi Kasei."
 "This collaboration will help Mitsubishi Kasei achieve its goal of actively expanding in the global pharmaceutical business, as well as preparing for increased direct involvement in the North American market in the 21st Century," said Masahiko Furukawa, president of Mitsubishi Kasei. "We are very pleased to begin this relationship with Marion Merrell Dow."
 Headquartered in Tokyo, Mitsubishi Kasei is Japan's premier diversified chemical company, with product lines that contribute to practically all aspects of life and industry. Headquartered in Kansas City, Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life.
 -0- 4/8/93
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/


CO: Marion Merrell Dow Inc.; Mitsubishi Kasei Corp. ST: Missouri IN: CHM MTC SU: JVN

EH -- LA015 -- 4130 04/08/93 09:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1993
Words:365
Previous Article:L.A. GEAR REPORTS FIRST QUARTER LOSS
Next Article:DRECO ENERGY SERVICES LTD. ANNOUNCES RESULTS
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION ON DRUGS FOR DIABETES AND AGING
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
SCIOS INC. AND MARION MERRELL DOW SIGN MAJOR RESEARCH AND DEVELOPMENT AGREEMENT TO DEVELOP NEW THERAPIES FOR ALZHEIMER'S DISEASE
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
MARION MERRELL DOW IN-LICENSES TWO DRUGS IN LATE-STAGE TRIALS FROM MERCK & CO.
ONCOGENE SCIENCE, INC. AND MARION MERRELL DOW COLLABORATIVE PROGRAM ADVANCES
MARION MERRELL DOW INC. TO CO-PROMOTE PRILOSEC(R) WITH ASTRA MERCK INC. IN THE UNITED STATES
MARION MERRELL DOW AND TEVA TO COLLABORATE ON MARKETING OF MULTIPLE SCLEROSIS TREATMENT
HOECHST MARION ROUSSEL AND SCIOS CONCLUDE RESEARCH AGREEMENT FOR ALZHEIMER'S DISEASE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters